$PTGX
Protagonist Therapeutics, Inc

2021 Q3 Form 10-Q Financial Statement

#000155837021010244 Filed on August 04, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q2
Revenue $10.29M $2.265M $6.220M
YoY Change -21.56% -63.59% -175.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.256M $6.715M $4.180M
YoY Change 48.38% 60.65% 8.29%
% of Gross Profit
Research & Development $36.96M $26.43M $20.26M
YoY Change 131.05% 30.48% 4.66%
% of Gross Profit
Depreciation & Amortization $213.0K $185.0K $200.0K
YoY Change 18.33% -7.5% 11.11%
% of Gross Profit
Operating Expenses $44.21M $33.15M $24.43M
YoY Change 111.68% 35.66% 5.24%
Operating Profit -$33.93M -$30.88M -$18.22M
YoY Change 336.52% 69.52% -42.0%
Interest Expense $122.0K $97.00K $209.0K
YoY Change 542.11% -53.59% -65.17%
% of Operating Profit
Other Income/Expense, Net $0.00 -$57.00K $512.0K
YoY Change -100.0% -111.13% -1483.78%
Pretax Income -$33.80M -$30.84M -$18.29M
YoY Change 335.45% 68.61% -40.62%
Income Tax $0.00 $0.00 $1.100M
% Of Pretax Income
Net Earnings -$33.80M -$30.84M -$19.42M
YoY Change 335.45% 58.81% -33.43%
Net Earnings / Revenue -328.64% -1361.68% -312.23%
Basic Earnings Per Share -$0.70 -$0.69
Diluted Earnings Per Share -$704.4K -$0.69 -$592.1K
COMMON SHARES
Basic Shares Outstanding 47.55M 44.86M
Diluted Shares Outstanding 47.99M 44.86M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $314.3M $354.3M $208.7M
YoY Change 62.01% 69.76% 65.5%
Cash & Equivalents $120.5M $192.4M $146.2M
Short-Term Investments $193.8M $161.9M $62.40M
Other Short-Term Assets $8.877M $7.683M $5.500M
YoY Change 30.54% 39.69% 12.24%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $327.7M $371.8M $217.5M
YoY Change 60.51% 70.98% 58.39%
LONG-TERM ASSETS
Property, Plant & Equipment $1.723M $1.718M $1.553M
YoY Change 18.09% 10.62% -81.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $38.17M $26.12M
YoY Change 536.15%
Other Assets $225.0K $225.0K $500.0K
YoY Change -55.0% -55.0% -80.77%
Total Long-Term Assets $45.49M $32.41M $7.514M
YoY Change 245.42% 331.38% -30.43%
TOTAL ASSETS
Total Short-Term Assets $327.7M $371.8M $217.5M
Total Long-Term Assets $45.49M $32.41M $7.514M
Total Assets $373.2M $404.2M $225.0M
YoY Change 71.72% 79.67% 51.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $706.0K $7.905M $2.855M
YoY Change -74.76% 176.88% 1.96%
Accrued Expenses $33.06M $20.10M $12.92M
YoY Change 113.05% 55.58% 7.64%
Deferred Revenue $2.241M $2.009M $17.23M
YoY Change -86.63% -88.34%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $39.16M $42.97M $35.36M
YoY Change 1.54% 21.53% 6.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $121.0K $121.0K $92.00K
YoY Change -28.82% 31.52% -99.7%
Total Long-Term Liabilities $121.0K $121.0K $92.00K
YoY Change -28.82% 31.52% -99.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $39.16M $42.97M $35.36M
Total Long-Term Liabilities $121.0K $121.0K $92.00K
Total Liabilities $43.52M $46.79M $57.50M
YoY Change -8.83% -18.63% -9.88%
SHAREHOLDERS EQUITY
Retained Earnings -$372.5M -$338.7M -$257.2M
YoY Change 40.62% 31.69%
Common Stock $702.3M $696.2M $424.9M
YoY Change 61.6% 63.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $329.7M $357.4M $167.5M
YoY Change
Total Liabilities & Shareholders Equity $373.2M $404.2M $225.0M
YoY Change 71.72% 79.67% 51.91%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q2
OPERATING ACTIVITIES
Net Income -$33.80M -$30.84M -$19.42M
YoY Change 335.45% 58.81% -33.43%
Depreciation, Depletion And Amortization $213.0K $185.0K $200.0K
YoY Change 18.33% -7.5% 11.11%
Cash From Operating Activities -$28.47M -$23.70M -$21.48M
YoY Change 74.77% 10.32% -685.29%
INVESTING ACTIVITIES
Capital Expenditures -$265.0K -$500.0K -$130.0K
YoY Change 231.25% 284.62% -85.39%
Acquisitions
YoY Change
Other Investing Activities -$44.44M $8.270M -$5.040M
YoY Change -17.78% -264.09% -59.12%
Cash From Investing Activities -$44.71M $7.770M -$5.170M
YoY Change -17.39% -250.29% -60.92%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.381M 125.4M 112.6M
YoY Change -81.99% 11.38% 959.08%
NET CHANGE
Cash From Operating Activities -28.47M -23.70M -21.48M
Cash From Investing Activities -44.71M 7.770M -5.170M
Cash From Financing Activities 1.381M 125.4M 112.6M
Net Change In Cash -71.80M 109.5M 85.93M
YoY Change 14.43% 27.39% 7930.84%
FREE CASH FLOW
Cash From Operating Activities -$28.47M -$23.70M -$21.48M
Capital Expenditures -$265.0K -$500.0K -$130.0K
Free Cash Flow -$28.21M -$23.20M -$21.35M
YoY Change 74.0% 8.65% -568.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47525560
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43745465
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
dei Entity Central Index Key
EntityCentralIndexKey
0001377121
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37852
dei Entity Registrant Name
EntityRegistrantName
PROTAGONIST THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0505495
dei Entity Address Address Line1
EntityAddressAddressLine1
7707 Gateway Boulevard, Suite 140
dei Entity Address City Or Town
EntityAddressCityOrTown
Newark
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei City Area Code
CityAreaCode
510
dei Local Phone Number
LocalPhoneNumber
474-0170
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94560-1160
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
121000
CY2021Q2 us-gaap Liabilities
Liabilities
46785000
CY2020Q4 us-gaap Liabilities
Liabilities
44862000
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
PTGX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47550573
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192412000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117358000
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
161868000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
188451000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
10000
CY2021Q2 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
7077000
CY2020Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
2426000
CY2021Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
2778000
CY2020Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1084000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7683000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6277000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
371818000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
315606000
CY2021Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
26122000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2000000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1718000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1462000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
450000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4349000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4950000
CY2021Q2 us-gaap Assets
Assets
404232000
CY2020Q4 us-gaap Assets
Assets
324468000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
7905000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3075000
CY2021Q2 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
11396000
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2732000
CY2021Q2 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
20096000
CY2020Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
18498000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2009000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
14477000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1567000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1459000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
42973000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40241000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3691000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4500000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
121000
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47525560
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43745465
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
696157000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
563389000
CY2021Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-59000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-338651000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-283811000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
357447000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
279606000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
404232000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
324468000
CY2021Q2 ptgx Revenue From Contract With Customer Including Cumulative Catch Up Adjustment To Revenue Modification Of Contract
RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract
2265000
CY2020Q2 ptgx Revenue From Contract With Customer Including Cumulative Catch Up Adjustment To Revenue Modification Of Contract
RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract
6217000
ptgx Revenue From Contract With Customer Including Cumulative Catch Up Adjustment To Revenue Modification Of Contract
RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract
8454000
ptgx Revenue From Contract With Customer Including Cumulative Catch Up Adjustment To Revenue Modification Of Contract
RevenueFromContractWithCustomerIncludingCumulativeCatchUpAdjustmentToRevenueModificationOfContract
9864000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26432000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20257000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
50677000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39025000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6715000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4177000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12680000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8753000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
33147000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
24434000
us-gaap Operating Expenses
OperatingExpenses
63357000
us-gaap Operating Expenses
OperatingExpenses
47778000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30882000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-18217000
us-gaap Operating Income Loss
OperatingIncomeLoss
-54903000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37914000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
97000
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
207000
us-gaap Investment Income Interest
InvestmentIncomeInterest
199000
us-gaap Investment Income Interest
InvestmentIncomeInterest
733000
CY2020Q2 us-gaap Interest Expense
InterestExpense
209000
us-gaap Interest Expense
InterestExpense
452000
CY2020Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-585000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-585000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-57000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
512000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-136000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30251805
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32799691
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44546172
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30842000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18292000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54840000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38196000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1129000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1305000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30842000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-19421000
us-gaap Net Income Loss
NetIncomeLoss
-54840000
us-gaap Net Income Loss
NetIncomeLoss
-39501000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44864637
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30842000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-19421000
us-gaap Net Income Loss
NetIncomeLoss
-54840000
us-gaap Net Income Loss
NetIncomeLoss
-39501000
CY2021Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-34000
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-324000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-67000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
14000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-20000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30868000
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19736000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54927000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-39488000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
259334000
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
123798000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1247000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3936000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-26000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30842000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
357447000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
62666000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
105331000
CY2020Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
585000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1996000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-315000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-19421000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
167485000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
279606000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
123798000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2563000
ptgx Shares Withheld For Net Settlements Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementsOfTaxWithholdingUponVestingOfRestrictedStockUnits
189000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6596000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-87000
us-gaap Net Income Loss
NetIncomeLoss
-54840000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
357447000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
79964000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
105331000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
991000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4044000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
13000
us-gaap Net Income Loss
NetIncomeLoss
-39501000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
167485000
us-gaap Profit Loss
ProfitLoss
-54840000
us-gaap Profit Loss
ProfitLoss
-39501000
us-gaap Share Based Compensation
ShareBasedCompensation
6596000
us-gaap Share Based Compensation
ShareBasedCompensation
4044000
ptgx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
887000
ptgx Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
887000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
365000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
419000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-821000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
243000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-585000
ptgx Amortization Of Debt Issuance Costs And Debt Instrument Accretion Of Final Payment Fee
AmortizationOfDebtIssuanceCostsAndDebtInstrumentAccretionOfFinalPaymentFee
22000
us-gaap Income Tax Credits And Adjustments
IncomeTaxCreditsAndAdjustments
1412000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
1682000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
278000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
4651000
us-gaap Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
-3758000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1421000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
248000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4874000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
73000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
8664000
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-259000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1386000
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
382000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-12468000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-7517000
us-gaap Operating Lease Payments
OperatingLeasePayments
987000
us-gaap Operating Lease Payments
OperatingLeasePayments
958000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
92000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52456000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37330000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
163460000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
66753000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
165080000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
104583000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
640000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
271000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
980000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37559000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
123995000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
105689000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2563000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
991000
ptgx Shares Withheld For Net Settlement Of Tax Withholding Upon Vesting Of Restricted Stock Units
SharesWithheldForNetSettlementOfTaxWithholdingUponVestingOfRestrictedStockUnits
189000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
14000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
10524000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
126369000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
112976000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-74000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
74819000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
113236000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
117818000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33466000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192637000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146702000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
63000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
21000
CY2021Q2 ptgx Cash Cash Equivalents And Marketable Securities Carrying Value
CashCashEquivalentsAndMarketableSecuritiesCarryingValue
380400000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-338700000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, accruals for research and development activities, stock-based compensation, income taxes, marketable securities and leases. Estimates related to revenue recognition include actual costs incurred versus total estimated costs of the Company’s deliverables to determine percentage of completion in addition to the application and estimates of potential revenue constraints in the determination of the transaction price under its license and collaboration agreements. Management bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to forecasted amounts and future events. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Due to the ongoing COVID-19 pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company has taken into consideration any known COVID-19 impacts in its accounting estimates to date and is not aware of any additional specific events or circumstances that would require any additional updates to its estimates or judgments or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates may change as new events occur and additional information is obtained. Actual results could differ materially from these estimates under different assumptions or conditions.</p>
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192637000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
146702000
ptgx Threshold Number Of Performance Obligation To Allocate Transaction Price
ThresholdNumberOfPerformanceObligationToAllocateTransactionPrice
1
us-gaap Revenue Practical Expedient Financing Component
RevenuePracticalExpedientFinancingComponent
true
ptgx Potential Qualified Discount Federal Income Tax Credit
PotentialQualifiedDiscountFederalIncomeTaxCredit
25
CY2021Q2 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
400000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
1500000
CY2020Q2 us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
2100000
us-gaap Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized
ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized
3300000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash, cash equivalents and marketable securities. Substantially all of the Company’s cash is held by two financial institutions </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and to meet liquidity requirements. The Company’s cash equivalents and marketable securities are managed by external managers within the guidelines of the Company’s investment policy. The Company’s investment policy addresses the level of credit exposure by limiting concentration in any one corporate issuer and establishing a minimum allowable credit rating. To manage its credit risk exposure, the Company maintains its U.S portfolio of cash equivalents and marketable securities in fixed income securities denominated and payable in U.S. dollars. Permissible investments of fixed income securities include obligations of the U.S. government and its agencies, money market instruments including commercial paper and negotiable certificates of deposit, highly rated corporate debt obligations and money market funds, and highly rated supranational and sovereign government securities. </span></p>
CY2021Q2 ptgx Cash Number Of Financial Institutions
CashNumberOfFinancialInstitutions
2
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192412000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
146242000
CY2020Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
10000
CY2021Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
225000
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
450000
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
96300000
CY2021Q2 ptgx Cash Equivalents And Marketable Securities Amortized Cost
CashEquivalentsAndMarketableSecuritiesAmortizedCost
373008000
CY2021Q2 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Gain
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
8000
CY2021Q2 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Loss
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
26000
CY2021Q2 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
372990000
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
185000000
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
161868000
CY2021Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
26122000
CY2021Q2 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
372990000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Amortized Cost
CashEquivalentsAndMarketableSecuritiesAmortizedCost
304142000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Gain
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedGain
12000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Gross Unrealized Loss
CashEquivalentsAndMarketableSecuritiesGrossUnrealizedLoss
10000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
304144000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
113693000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
188451000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2000000
CY2020Q4 ptgx Cash Equivalents And Marketable Securities Fair Value
CashEquivalentsAndMarketableSecuritiesFairValue
304144000
CY2021Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
161900000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
188500000
ptgx Current Contractual Maturities Maximum Period
CurrentContractualMaturitiesMaximumPeriod
P1Y
CY2020 ptgx Current Contractual Maturities Maximum Period
CurrentContractualMaturitiesMaximumPeriod
P1Y
CY2021Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
26100000
CY2020Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2000000.0
ptgx Noncurrent Contractual Maturities Minimum Period
NoncurrentContractualMaturitiesMinimumPeriod
P1Y
CY2020 ptgx Noncurrent Contractual Maturities Minimum Period
NoncurrentContractualMaturitiesMinimumPeriod
P1Y
ptgx Noncurrent Contractual Maturities Maximum Period
NoncurrentContractualMaturitiesMaximumPeriod
P2Y
CY2020 ptgx Noncurrent Contractual Maturities Maximum Period
NoncurrentContractualMaturitiesMaximumPeriod
P2Y
CY2021Q2 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
14976000
CY2020Q4 ptgx Accrued Clinical And Research Related Expenses Current
AccruedClinicalAndResearchRelatedExpensesCurrent
11335000
CY2021Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3780000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
6413000
CY2021Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
829000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
668000
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
511000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
82000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20096000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18498000
CY2014 ptgx Number Of Development Milestone Payments
NumberOfDevelopmentMilestonePayments
3
CY2014 ptgx Aggregate Amount Of Development Milestone Payment
AggregateAmountOfDevelopmentMilestonePayment
1000000.0
ptgx Aggregate Amount Of Development Milestone Payment
AggregateAmountOfDevelopmentMilestonePayment
0
CY2020Q2 ptgx Aggregate Amount Of Development Milestone Payment
AggregateAmountOfDevelopmentMilestonePayment
0
ptgx Aggregate Amount Of Development Milestone Payment
AggregateAmountOfDevelopmentMilestonePayment
0
CY2021Q2 ptgx Aggregate Amount Of Development Milestone Payment
AggregateAmountOfDevelopmentMilestonePayment
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7588812
CY2020Q2 ptgx Percentage Of Employee Base Impacted By Restructuring Plan
PercentageOfEmployeeBaseImpactedByRestructuringPlan
0.12
CY2020Q2 us-gaap Restructuring Charges
RestructuringCharges
300000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4648120
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.87
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y7M9D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
40000000.0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1597040
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
26.97
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
177152
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
11.54
us-gaap Stock Issued During Period Shares Restricted Stock Award Forfeited
StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
106672
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.66
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5961336
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M7D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
173100000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2980187
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.39
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y5M15D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
96800000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5961336
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M7D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
173100000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
19.79
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.880
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.888
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.743
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.745
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.880
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.902
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.721
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.745
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0085
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0111
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0039
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0042
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0111
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0144
CY2020 ptgx Expected Volatility Calculation Percentage Of Average Volatility Expected Term Of Stock Option Grants
ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants
0.75
CY2020 ptgx Expected Volatility Calculation Percentage Of Volatility Of Stock Price Since Ipo
ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo
0.25
CY2021Q1 ptgx Expected Volatility Calculation Percentage Of Average Volatility Expected Term Of Stock Option Grants
ExpectedVolatilityCalculationPercentageOfAverageVolatilityExpectedTermOfStockOptionGrants
0.50
CY2021Q1 ptgx Expected Volatility Calculation Percentage Of Volatility Of Stock Price Since Ipo
ExpectedVolatilityCalculationPercentageOfVolatilityOfStockPriceSinceIpo
0.50
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3936000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1996000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6596000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4044000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
46400000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
3500
CY2021Q2 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
0
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1300000
CY2020Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.062
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.034
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-30842000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-19421000
us-gaap Net Income Loss
NetIncomeLoss
-54840000
us-gaap Net Income Loss
NetIncomeLoss
-39501000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44864637
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32799691
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44546172
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30251805
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.23
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9260957

Files In Submission

Name View Source Status
0001558370-21-010244-index-headers.html Edgar Link pending
0001558370-21-010244-index.html Edgar Link pending
0001558370-21-010244.txt Edgar Link pending
0001558370-21-010244-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ptgx-20210630.xsd Edgar Link pending
ptgx-20210630x10q.htm Edgar Link pending
ptgx-20210630x10q007.jpg Edgar Link pending
ptgx-20210630x10q_htm.xml Edgar Link completed
ptgx-20210630xex31d1.htm Edgar Link pending
ptgx-20210630xex31d2.htm Edgar Link pending
ptgx-20210630xex32d1.htm Edgar Link pending
ptgx-20210630_cal.xml Edgar Link unprocessable
ptgx-20210630_def.xml Edgar Link unprocessable
ptgx-20210630_lab.xml Edgar Link unprocessable
ptgx-20210630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending